Ryan A Mcconnell, MD
Gastroenterology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 3 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
3 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mcconnell’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
3 of 3 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A129683 · Current
Licensed to practise in California · since 2014 · expires 2028-04-30 · Baylor College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$64,468
Medicare paid this office $64,468 for 251 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 165 | $39,453 | $239 |
| Long return visit (40+ min) | 57 | $11,934 | $163 |
| Biopsy of large bowel using a flexible endoscope | 61 | $3,049 | $49 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | $1,946 | $81 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 179 | $843 | $5 |
See all 6 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 165 | $39,453 | $239 |
| Long return visit (40+ min) | 57 | $11,934 | $163 |
| Biopsy of large bowel using a flexible endoscope | 61 | $3,049 | $49 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | $1,946 | $81 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 179 | $843 | $5 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 45 | $751 | $14 |
Procedures Medicare counted
| Colonoscopy | 39 | More than 59% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 16 | More than 47% of doctors who do this |
Who their Medicare patients are
251 Original Medicare patients in 2024. Average age 74 · Women 54% · Health risk score 0.82. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 50% · Cancer 19% · Coronary heart disease 18% · Diabetes 14% · Depression 12% · Chronic kidney disease 11% · Atrial fibrillation 8%.
The office billed $684,290, Medicare allowed $79,065 and paid $64,468; for 621 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 251 | 621 | 74 | 0.82 | $684,290 | $64,468 |
| 2023 | 236 | 546 | 74 | 0.80 | $596,224 | $60,842 |
| 2022 | 219 | 525 | 74 | 0.82 | $540,028 | $55,784 |
| 2021 | 243 | 734 | 74 | 0.78 | $628,932 | $68,924 |
| 2020 | 184 | 448 | 73 | 0.87 | $461,025 | $45,277 |
| 2019 | 221 | 605 | 74 | 0.82 | $539,995 | $54,681 |
| 2018 | 220 | 718 | 73 | 0.87 | $530,285 | $52,586 |
| 2017 | 77 | 256 | 73 | 0.92 | $156,234 | $17,723 |
| 2013 | 11 | 14 | 61 | 3.96 | $3,234 | $646 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 144 | $35,649 | $244 |
| Long return visit (40+ min) | 59 | $11,355 | $158 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 37 | $3,135 | $85 |
| Biopsy of large bowel using a flexible endoscope | 49 | $2,854 | $58 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $928 | $29 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 161 | $764 | $5 |
2022: 7 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 138 | $32,338 | $231 |
| Long return visit (40+ min) | 56 | $10,759 | $166 |
| Biopsy of large bowel using a flexible endoscope | 42 | $3,086 | $70 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 22 | $1,538 | $70 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $1,104 | $31 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 147 | $719 | $5 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $544 | $23 |
2021: 6 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 137 | $32,336 | $236 |
| Long return visit (40+ min) | 67 | $15,015 | $161 |
| Biopsy of large bowel using a flexible endoscope | 79 | $4,989 | $62 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 32 | $2,539 | $77 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $1,964 | $31 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 168 | $836 | $5 |
2020: 7 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 97 | $23,446 | $242 |
| Long return visit (40+ min) | 36 | $5,568 | $139 |
| Biopsy of large bowel using a flexible endoscope | 70 | $3,636 | $52 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $1,727 | $82 |
| Return visit (30+ min) | 20 | $1,499 | $71 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 124 | $621 | $5 |
| Injection beneath lining of large bowel using a flexible endoscope | 11 | $166 | $15 |
2019: 7 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 98 | $23,537 | $238 |
| Long return visit (40+ min) | 55 | $9,911 | $132 |
| Biopsy of large bowel using a flexible endoscope | 92 | $6,409 | $68 |
| New patient visit (45+ min) | 16 | $2,306 | $144 |
| Return visit (30+ min) | 21 | $1,886 | $86 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $1,690 | $80 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 129 | $643 | $5 |
2018: 9 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 81 | $18,758 | $232 |
| Biopsy of large bowel using a flexible endoscope | 110 | $9,771 | $88 |
| Long return visit (40+ min) | 34 | $5,509 | $134 |
| New patient visit (45+ min) | 22 | $3,222 | $146 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,545 | $91 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 99 | $2,222 | $12 |
| Extended patient service without direct patient contact, first hour | 17 | $1,509 | $89 |
| Return visit (30+ min) | 13 | $1,224 | $94 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 154 | $738 | $5 |
2017: 4 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | $4,509 | $225 |
| Biopsy of large bowel using a flexible endoscope | 33 | $3,383 | $103 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 43 | $1,002 | $11 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 46 | $216 | $5 |
Drugs they prescribed that Part D paid
$4,008,954
Pharmacies billed $4,008,954 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 641) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
318 generic and 307 brand-name prescriptions · $4,008,954 in drug cost · 25 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 92 | $2,519,536 | $27,386 |
| Humira(Cf) | 50 | $561,300 | $11,226 |
| Skyrizi on-Body | 22 | $454,978 | $20,681 |
| Rinvoq | 39 | $331,576 | $8,502 |
| Mesalamine | 40 | $23,580 | $590 |
See all 13 drugs
| Stelara | 92 | $2,519,536 | $27,386 |
| Humira(Cf) | 50 | $561,300 | $11,226 |
| Skyrizi on-Body | 22 | $454,978 | $20,681 |
| Rinvoq | 39 | $331,576 | $8,502 |
| Mesalamine | 40 | $23,580 | $590 |
| Budesonide | 12 | $10,526 | $877 |
| Sod Sulf-Potass Sulf-Mag Sulf | 133 | $8,719 | $66 |
| Opium Tincture | 16 | $8,447 | $528 |
| Balsalazide Disodium | 28 | $5,544 | $198 |
| Cholestyramine | 17 | $1,518 | $89 |
| Famotidine | 19 | $336 | $18 |
| Peg 3350-Electrolyte | 16 | $292 | $18 |
| Omeprazole | 18 | $77 | $4 |
Year by year
| 2024 | 641 | 217 | 0% (0) | 48% | $4,008,954 |
| 2023 | 492 | 183 | 0% (0) | 47% | $2,868,308 |
| 2022 | 485 | 170 | 0% (0) | 51% | $2,525,517 |
| 2021 | 544 | 215 | None | 49% | $1,285,303 |
| 2020 | 428 | 157 | 0% (0) | None | $728,056 |
| 2019 | 425 | 198 | 0% (0) | None | $375,004 |
| 2018 | 274 | 169 | None | 40% | $314,933 |
| 2017 | 86 | 66 | 0% (0) | 64% | $41,953 |
| 2013 | 17 | None | None | None | $512 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Stelara | 89 | $2,402,662 | $26,996 |
| Humira(Cf) | 25 | $281,223 | $11,249 |
| Mesalamine | 21 | $18,473 | $880 |
| Opium Tincture | 22 | $17,552 | $798 |
| Balsalazide Disodium | 43 | $10,000 | $233 |
| Sod Sulf-Potass Sulf-Mag Sulf | 97 | $7,577 | $78 |
| Cholestyramine | 18 | $2,805 | $156 |
| Peg 3350-Electrolyte | 20 | $465 | $23 |
| Omeprazole | 12 | $352 | $29 |
| Pantoprazole | 11 | $215 | $20 |
2022: 12 drugs
| Stelara | 90 | $2,296,568 | $25,517 |
| Mesalamine | 21 | $21,821 | $1,039 |
| Opium Tincture | 23 | $17,065 | $742 |
| Suprep | 79 | $9,083 | $115 |
| Balsalazide Disodium | 54 | $7,890 | $146 |
| Trulance | 12 | $6,454 | $538 |
| Cholestyramine | 16 | $3,576 | $224 |
| Azathioprine | 17 | $1,440 | $85 |
| Peg 3350-Electrolyte | 20 | $342 | $17 |
| Omeprazole | 11 | $240 | $22 |
| Amitriptyline | 13 | $169 | $13 |
| Famotidine | 11 | $117 | $11 |
2021: 13 drugs
| Stelara | 39 | $975,052 | $25,001 |
| Humira(Cf) | 13 | $163,869 | $12,605 |
| Mesalamine | 45 | $45,399 | $1,009 |
| Suprep | 125 | $13,834 | $111 |
| Balsalazide Disodium | 46 | $10,363 | $225 |
| Trulance | 11 | $5,475 | $498 |
| Clenpiq | 13 | $2,108 | $162 |
| Azathioprine | 23 | $1,986 | $86 |
| Methotrexate | 19 | $701 | $37 |
| Famotidine | 20 | $415 | $21 |
| Omeprazole | 21 | $369 | $18 |
| Peg 3350-Electrolyte | 20 | $362 | $18 |
| Pantoprazole | 11 | $298 | $27 |
2020: 11 drugs
| Stelara | 20 | $469,666 | $23,483 |
| Humira(Cf) | 12 | $114,796 | $9,566 |
| Mesalamine | 25 | $18,725 | $749 |
| Suprep | 93 | $10,021 | $108 |
| Balsalazide Disodium | 25 | $6,954 | $278 |
| Budesonide Ec | 11 | $5,444 | $495 |
| Cholestyramine | 34 | $5,328 | $157 |
| Azathioprine | 22 | $2,668 | $121 |
| Omeprazole | 20 | $369 | $18 |
| Peg 3350-Electrolyte | 16 | $262 | $16 |
| Famotidine | 17 | $244 | $14 |
2019: 8 drugs
| Mesalamine | 46 | $29,138 | $633 |
| Suprep | 118 | $11,911 | $101 |
| Balsalazide Disodium | 32 | $7,666 | $240 |
| Cholestyramine | 18 | $2,325 | $129 |
| Azathioprine | 17 | $1,639 | $96 |
| Omeprazole | 28 | $543 | $19 |
| Peg 3350-Electrolyte | 18 | $320 | $18 |
| Gavilyte-N | 11 | $195 | $18 |
2018: 7 drugs
| Humira | 20 | $143,152 | $7,158 |
| Mesalamine | 14 | $17,348 | $1,239 |
| Suprep | 24 | $2,260 | $94 |
| Peg 3350-Electrolyte | 59 | $1,025 | $17 |
| Gavilyte-N | 33 | $557 | $17 |
| Omeprazole | 21 | $357 | $17 |
| Gavilyte-C | 11 | $113 | $10 |
2017: 3 drugs
| Budesonide Ec | 11 | $6,669 | $606 |
| Peg 3350-Electrolyte | 35 | $499 | $14 |
| Gavilyte-N | 14 | $241 | $17 |
Money from drug and device companies
$71,075 in 2025
| 2025 | 7 | 81 | $67,236 | $71,075 |
| 2024 | 7 | 56 | $48,144 | $50,141 |
| 2023 | 7 | 39 | $32,941 | $34,150 |
| 2022 | 6 | 33 | $21,416 | $23,536 |
| 2021 | 3 | 5 | $4,900 | $4,900 |
| 2020 | 2 | 5 | $6,900 | $6,984 |
| 2019 | 2 | 9 | $6,000 | $6,281 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $28,522 | 30 payments
|
| Abbvie | Skyrizi | $15,249 | 21 payments
|
| Lilly USA | Omvoh | $12,694 | 17 payments
|
| Pfizer | Velsipity | $9,722 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $4,686 | 6 payments
|
| Genzyme | Dupixent | $123 | 1 payment
|
See all 81 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-30 | Entyvio | $53 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-12-30 | Entyvio | $94 |
| Abbvie | Consulting · 2025-12-19 | None | $575 |
| Abbvie | Paid to speak or teach · 2025-12-18 | Rinvoq | $1,150 |
| Abbvie | Paid to speak or teach · 2025-12-04 | Skyrizi | $2,875 |
| Abbvie | Meals · 2025-12-04 | Skyrizi | $123 |
| Abbvie | Paid to speak or teach · 2025-12-01 | Skyrizi | $2,875 |
| Takeda Pharmaceuticals U.S.A. | Paid to speak or teach · 2025-12-01 | Entyvio | $1,685 |
| Janssen Biotech | Travel · 2025-11-17 | Tremfya | $70 |
| Janssen Biotech | Meals · 2025-11-17 | Tremfya | $53 |
| Lilly USA | Paid to speak or teach · 2025-11-17 | Omvoh | $1,000 |
| Janssen Biotech | Paid to speak or teach · 2025-11-11 | Tremfya | $3,150 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-11-09 | Entyvio | $519 |
| Abbvie | Meals · 2025-11-06 | Skyrizi | $154 |
| Janssen Biotech | Meals · 2025-10-29 | Tremfya | $37 |
| Janssen Biotech | Travel · 2025-10-28 | Tremfya | $21 |
| Abbvie | Travel · 2025-10-28 | Skyrizi | $42 |
| Janssen Biotech | Paid to speak or teach · 2025-10-25 | Stelara | $1,400 |
| Janssen Biotech | Paid to speak or teach · 2025-10-25 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-10-23 | Tremfya | $139 |
| Lilly USA | Meals · 2025-10-22 | Omvoh | $24 |
| Abbvie | Meals · 2025-10-18 | Rinvoq | $27 |
| Janssen Biotech | Meals · 2025-10-13 | Tremfya | $19 |
| Janssen Biotech | Meals · 2025-10-08 | Tremfya | $17 |
| Janssen Biotech | Travel · 2025-10-08 | Tremfya | $65 |
| Abbvie | Paid to speak or teach · 2025-10-08 | Skyrizi | $2,875 |
| Janssen Biotech | Paid to speak or teach · 2025-10-04 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-10-02 | Tremfya | $126 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-02 | Entyvio | $8 |
| Janssen Biotech | Paid to speak or teach · 2025-10-01 | Stelara | $1,050 |
| Abbvie | Meals · 2025-09-29 | Rinvoq | $27 |
| Abbvie | Meals · 2025-09-25 | Skyrizi | $122 |
| Abbvie | Meals · 2025-09-05 | Linzess | $31 |
| Janssen Biotech | Meals · 2025-08-27 | Tremfya | $30 |
| Pfizer | Paid to speak or teach · 2025-08-27 | Velsipity | $3,125 |
| Genzyme | Meals · 2025-08-20 | Dupixent | $123 |
| Abbvie | Travel · 2025-07-14 | Skyrizi | $3 |
| Abbvie | Travel · 2025-07-14 | Skyrizi | $42 |
| Abbvie | Meals · 2025-07-10 | Linzess | $8 |
| Abbvie | Meals · 2025-07-08 | Rinvoq | $16 |
| Abbvie | Paid to speak or teach · 2025-06-25 | Skyrizi | $2,875 |
| Abbvie | Meals · 2025-06-05 | Skyrizi | $125 |
| Abbvie | Meals · 2025-05-30 | Creon | $8 |
| Lilly USA | Meals · 2025-05-28 | Omvoh | $32 |
| Janssen Biotech | Paid to speak or teach · 2025-05-24 | Tremfya | $4,900 |
| Janssen Biotech | Travel · 2025-05-19 | Tremfya | $103 |
| Janssen Biotech | Travel · 2025-05-17 | Tremfya | $350 |
| Janssen Biotech | Paid to speak or teach · 2025-05-17 | Tremfya | $3,150 |
| Janssen Biotech | Travel · 2025-05-15 | Tremfya | $15 |
| Janssen Biotech | Meals · 2025-05-15 | Tremfya | $130 |
| Lilly USA | Travel · 2025-05-12 | Omvoh | $10 |
| Lilly USA | Paid to speak or teach · 2025-05-07 | Omvoh | $750 |
| Lilly USA | Paid to speak or teach · 2025-05-07 | Omvoh | $2,000 |
| Janssen Biotech | Meals · 2025-05-05 | Tremfya | $150 |
| Janssen Biotech | Paid to speak or teach · 2025-05-03 | Tremfya | $2,100 |
| Lilly USA | Meals · 2025-05-03 | Omvoh | $52 |
| Lilly USA | Meals · 2025-05-01 | Omvoh | $125 |
| Janssen Biotech | Travel · 2025-04-28 | Tremfya | $75 |
| Janssen Biotech | Meals · 2025-04-28 | Tremfya | $16 |
| Lilly USA | Meals · 2025-04-28 | Omvoh | $35 |
| Janssen Biotech | Paid to speak or teach · 2025-04-26 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-04-24 | Tremfya | $126 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-04-11 | None | $2,329 |
| Lilly USA | Meals · 2025-04-01 | Omvoh | $35 |
| Abbvie | Paid to speak or teach · 2025-03-28 | Skyrizi | $1,150 |
| Pfizer | Consulting · 2025-03-27 | Velsipity | $3,125 |
| Pfizer | Paid to speak or teach · 2025-03-27 | Velsipity | $323 |
| Pfizer | Consulting · 2025-03-27 | Velsipity | $3,125 |
| Lilly USA | Paid to speak or teach · 2025-02-21 | Omvoh | $2,000 |
| Lilly USA | Consulting · 2025-02-21 | Omvoh | $1,750 |
| Lilly USA | Consulting · 2025-02-21 | Omvoh | $1,500 |
| Lilly USA | Travel · 2025-02-20 | Omvoh | $11 |
| Djo | Meals · 2025-02-14 | Chattanooga | $78 |
| Lilly USA | Paid to speak or teach · 2025-02-10 | Omvoh | $1,250 |
| Lilly USA | Paid to speak or teach · 2025-02-10 | Omvoh | $2,000 |
| Abbvie | Meals · 2025-02-07 | Rinvoq | $147 |
| Lilly USA | Meals · 2025-02-06 | Omvoh | $122 |
| Pfizer | Meals · 2025-02-06 | Velsipity | $24 |
| Janssen Biotech | Paid to speak or teach · 2025-01-20 | Tremfya | $1,700 |
| Janssen Biotech | Travel · 2025-01-07 | Tremfya | $22 |
| Janssen Biotech | Travel · 2025-01-07 | Tremfya | $60 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $50,141
| Janssen Biotech | Tremfya | $15,113 | 10 payments
|
| Lilly USA | Omvoh | $14,198 | 21 payments
|
| Abbvie | Skyrizi | $11,574 | 16 payments
|
| Pfizer | Velsipity | $6,587 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $1,242 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $819 | 2 payments
|
| Celgene | Zeposia | $607 | 2 payments
|
2023: $34,150
| Abbvie | Rinvoq | $16,493 | 19 payments
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $11,880 | 8 payments
|
| Lilly USA | None | $3,781 | 3 payments
|
| Janssen Biotech | Stelara | $1,043 | 1 payment
|
| Pfizer | Eucrisa | $600 | 1 payment
|
| Celgene | Zeposia | $337 | 6 payments
|
| Nestle Healthcare Nutrition | Vowst | $16 | 1 payment
|
2022: $23,536
| E.R. Squibb & Sons L.L.C. | Zeposia | $11,048 | 11 payments
|
| Abbvie | Skyrizi | $8,102 | 8 payments
|
| Pfizer | Xeljanz | $3,900 | 2 payments
|
| Celgene | Zeposia | $407 | 10 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $51 | 1 payment
|
| Janssen Biotech | Stelara | $28 | 1 payment
|
2021: $4,900
| AbbVie | Humira | $4,038 | 3 payments
|
| Janssen Biotech | Stelara | $563 | 1 payment
|
| Celgene | None | $300 | 1 payment
|
2020: $6,984
| AbbVie | Humira | $4,275 | 3 payments
|
| Pfizer | Xeljanz | $2,709 | 2 payments
|
2019: $6,281
| AbbVie | Humira | $6,268 | 8 payments
|
| Janssen Biotech | Stelara | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · Phiii Yellowstone Induction Study # 1 Ozanimod in Moderate To Severe Cd (Rpc01-3201) (Bms Study Number: Im047-P14) (Rpc01-3201) · 2019 | Their institution | $10,000 |
| Celgene Corporation · Ph III Yellowstone Cd Maintenance (Rpc01-3203) (Bms Study Number: Im047-P16) (Rpc01-3203) · 2019 | Their institution | $10,000 |
| Celgene Corporation · Ph III Yellowstone Cd Ole (Rpc01-3204) (Bms Study Number: Im047-P17) (Rpc01-3204) · 2019 | Their institution | $10,000 |
| Celgene Corporation · Phiii Yellowstone Induction Study # 1 Ozanimod in Moderate To Severe Cd (Rpc01-3201) (Bms Study Number: Im047-P14) · 2020 | Their institution | $1,500 |
| Celgene Corporation · Ph III Yellowstone Cd Ole (Rpc01-3204) (Bms Study Number: Im047-P17) · 2020 | Their institution | $1,500 |
| Celgene Corporation · Ph III Yellowstone Cd Maintenance (Rpc01-3203) (Bms Study Number: Im047-P16) · 2020 | Their institution | $1,500 |
| Celgene Corporation · A Phase 3, Multicenter, Open-Label Extension Study · 2021 | Their institution | $1,250 |
| Celgene Corporation · A Phase 3, Multicenter, Randomized, Double-Blind, · 2021 | Their institution | $1,250 |
| Celgene Corporation · Induction Study #1 - A Phase 3, Multicenter, Rando · 2021 | Their institution | $1,250 |
Professional record
- NPI
- 1013151588
- Licence
- CA A129683California A129683: Current · expires 2028-04-30
- Trained
- Baylor College of Medicine, 2009
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2009-04-28
- NPI last updated
- 2020-06-02
- NPI record certified
- 2020-06-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305